ପାଜୋପାନିବ

ପାଜୋପାନିବ
	<img src="//upload.wikimedia.org/wikipedia/commons/thumb/7/7a/Pazopanib.svg/275px-Pazopanib.svg.png" decoding="async" width="275" height="84" class="mw-file-element" data-file-width="512" data-file-height="156">
Clinical data
Pronunciation	/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade names	Votrient
AHFS/Drugs.com	monograph
MedlinePlus	a610013
data	EU EMA: yes; US DailyMed: Pazopanib;
Pregnancy; category	AU: D ; US: D (Evidence of risk) ; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	21% (14–39%)
Protein binding	>99.5%
Metabolism	Liver: CYP3A4 (major), 1A2 and 2C8 (minor)
Elimination half-life	30.9±4 hours
Excretion	Faeces (primary), urine (<4%)
Identifiers
	IUPAC name 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide;
Chemical and physical data
Formula	C21H23N7O2S
Molar mass	୪୩୭.୫୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C;
	InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H <img alt="check" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" decoding="async" width="7" height="7" class="mw-file-element" data-file-width="600" data-file-height="600"> ; Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N <img alt="check" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" decoding="async" width="7" height="7" class="mw-file-element" data-file-width="600" data-file-height="600"> ;
(verify)

ପାଜୋପାନିବ
Clinical data
Pronunciation	/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade names	Votrient
AHFS/Drugs.com	monograph
MedlinePlus	a610013
data	EU EMA: yes; US DailyMed: Pazopanib;
Pregnancy; category	AU: D ; US: D (Evidence of risk) ; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	21% (14–39%)
Protein binding	>99.5%
Metabolism	Liver: CYP3A4 (major), 1A2 and 2C8 (minor)
Elimination half-life	30.9±4 hours
Excretion	Faeces (primary), urine (<4%)
Identifiers
	IUPAC name 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide;
Chemical and physical data
Formula	C21H23N7O2S
Molar mass	୪୩୭.୫୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C;
	InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H ; Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N ;
(verify)

ପାଜୋପାନିବ (ଇଂରାଜୀ ଭାଷାରେ Pazopanib), Votrient ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ବୃକ୍‌କ ଜୀବକୋଷ କର୍କଟ ଓ କେତେକ କୋମଳ ତନ୍ତୁ ସାର୍କୋମାର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବ‌ହୃତ ହୁଏ ।^[୩] ଜୀବକୋଷ କର୍କଟ ଅନ୍ୟ ଔଷଧ ସାହାଯ୍ୟରେ ଭଲ ନ ହେଲ ଏହା ଦିଆଯାଏ । ଏହା ପାଟିରେ ଦିଆଯାଏ ।

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ଉଚ୍ଚ ରକ୍ତଚାପ, ଶ୍ୱେତ କେଶ, ଅଇ, ଥକ୍କାଣ, ପେଟ ଯନ୍ତ୍ରଣା, ସ୍ୱଳ୍ପ ରକ୍ତ କୋଷ ଓ ଯକୃତ ସମସ୍ୟା ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସ୍ୱଳ୍ପ ଥାଇରଏଡ, ରକ୍ତସ୍ରାବ, ଜମାଟ ବାନ୍ଧିବା ଓ ଜଠରାନ୍ତ୍ର ଛିଦ୍ର ହୋଇପାରେ । ଗର୍ଭାବସ୍ଥାରେ ଏହା ଦେଲେ ଶିଶୁର କ୍ଷତି କ୍ଷତି ହୋଇପାରେ । ଏହା ଏକ ଟାଇରୋସିନ କାଇନେଜ ପ୍ରତିରୋଧକ ।

୨୦୦୯ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ପାଜୋପାନିବ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୪] ୟୁରୋପରେ ଏହା ୨୦୧୦ରେ ସର୍ତ୍ତମୂଳକ ଅନୁମୋଦନ ଏବଂ ୨୦୧୩ରେ ସମ୍ପୂର୍ଣ୍ଣ ଅନୁମୋଦନ ଲାଭ କଲା ।^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ଏହାର ଚିକିତ୍ସାରେ ୨୦୨୧ ପ୍ରତି ମାସରେ ୨,୨୫୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୁଏ ।^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ସମାନ ପରିମାଣର ଔଷଧ ପାଇଁ ପ୍ରାୟ ୧୪,୨୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୁଏ ।^[୬]

ଆଧାର

,

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived (PDF) from the original on 9 October 2016. Retrieved 8 October 2016.
↑ ^୩.୦ ^୩.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1039. ISBN 978-0857114105.
↑ ^୪.୦ ^୪.୧ "PAZOPanib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 26 October 2021.
↑ "Votrient". Archived from the original on 22 October 2021. Retrieved 26 October 2021.
↑ "Pazopanib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 26 October 2021.

[MSR-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014.

[EMA_CHMP-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Archived (PDF) from the original on 9 October 2016. Retrieved 8 October 2016.

[BNF81-3] ୩.୦ ^୩.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1039. ISBN 978-0857114105.

[AHFS2021-4] ୪.୦ ^୪.୧ "PAZOPanib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 26 October 2021.

[EPAR2021-5] "Votrient". Archived from the original on 22 October 2021. Retrieved 26 October 2021.

[6] "Pazopanib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 26 October 2021.

[୩]

[୨]

[୧]

[୪]

[୫]

[୬]

Clinical data

Pronunciation	/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade names	Votrient
AHFS/Drugs.com	monograph
MedlinePlus	a610013
data	EU EMA: yes US DailyMed: Pazopanib
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	21% (14–39%)^[୨]
Protein binding	>99.5%^[୨]^[୧]
Metabolism	Liver: CYP3A4 (major), 1A2 and 2C8 (minor)^[୧]
Elimination half-life	30.9±4 hours^[୨]
Excretion	Faeces (primary), urine (<4%)^[୧]
Identifiers
IUPAC name 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide
Chemical and physical data
Formula	C₂₁H₂₃N₇O₂S
Molar mass	୪୩୭.୫୨ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C
InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H^Y Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N^Y
(verify)